Dr. Samantha Terry
Dr. Samantha Terry, a biologist, obtained her PhD in Radiation Biology with a focus on the mechanisms of radiation-induced chromosomal damage at the University of St Andrews, UK, in 2010. Her postdoc at the University of Oxford investigated the influence of the density of chromatin packing on the therapeutic efficacy of molecular radiotherapies. She then moved to an industry-funded postdoc on radionuclide imaging of the tumour microenvironment and monitoring therapy response in tumour and arthritis models at the Radboud UMC, Nijmegen, the Netherlands, in 2011.
Since 2015, Dr Terry has started her own research group at King’s College London, UK, to determine how radionuclides used for therapy affect either the cells they are targeting or off-target cells in order to predict how radionuclides and radiopharmaceuticals can be more efficacious. Questions to answer for a whole range of radionuclides, including those used in imaging, are:
o How can therapeutic radionuclides be used to maximize tumour cell kill for the same amount of radioactivity whilst minimizing damage to healthy tissues?
o How important is subcellular localisation?
o Are radionuclides more effective in metastases?
o Does bystander play a role in radionuclide therapy?
o How can radionuclides be made more effective, in terms of combination therapies?
o Are different cells more sensitive to certain types of radiation than others?
Dr Terry has received many grants from industry partners, several early career grants and is principal investigator on various research grants. She is also active on twitter (@syaterry) and acts on organizing committees for molecular radiotherapy meetings, as editorial board member for Nuclear Medicine and Biology, as well as member of the Inflammation and Infection Committee at the European Association of Nuclear Medicine.